CClinicalTrials.gg
Status unknownNCT03941470Updated May 8, 2019

Assessment of Natural Killer Cells in Unexplained Recurrent Pregnancy Loss

An observational study in Female, Recurrent Miscarriage and Unexplained Pregnancy Loss, sponsored by Assiut University. Status unknown at 1 site in Egypt. Open to female participants aged Up to 35 Years. Per ClinicalTrials.gov, last updated 2019-05-08.

Sponsored by Assiut University · Observational

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
60
Ages
Up to 35 Years
Sex
Female
01

Study summary

To assess natural killer cells frequency and activation in cases of unexplained recurrent abortion in comparison to fertile cases

    1. . To study the expression of stimulatory receptors of natural killer cell.
  • 3-To study the expression of inhibitory receptors of natural killer cell.
Read the detailed description

NK-cell functioning is controlled by a wide range of receptors that are expressed on the cell surface. These receptors are either inhibitory or activating in nature. The family of inhibitory receptors consists of the killer immunoglobulin-like receptors (KIR) or Ig-like receptors (CD158), the C type lectin receptors (CD94-NKG2A) and leukocyte inhibitory receptors (LIR1, LAIR-1). Activating receptors are the natural cytotoxic receptors (NKp46, NKp44), C type lectin receptors (NKG2D, CD94-NKG2C), and Ig-like receptors (2B4). A particular NK cell typically expresses two to four inhibitory receptors in addition to an array of activation receptors. The killing by NK cells is mediated through several activating NK receptors. Among these are NKG2D and the three natural cytotoxicity receptors (NCRs), NKp30, NKp44, and NKp46 (Yang et al., 2000) Osne of the natural cytotoxicity receptors (NCRs) NKp46, , is a unique marker that functions in NK cell cytotoxicity and cytokine production. Expression of NKp46 on NK cells is lower in women with recurrent pregnancy loss, so evaluation of NKp46 on peripheral blood NK cells may provide a means of screening for reproductive abnormalities (Fukui et al., 2015).

During pregnancy, decidual NK cells comprise ∼70-80% of the decidual lymphocytes and are considered a special NK subset that does not exert cytolytic functions against trophoblast cells and has generally reduced cytotoxicity (Hanna and Mandelboim, 2007).

These cells express activating NK receptors, including all the NCRs and NKG2D. However, instead of triggering cytotoxicity, these receptors act to stimulate secretion of cytokines and angiogenic factors, which are essential for trophoblast invasion and vascular modifications (Hanna et al., 2006).

One study reported that pNK cell levels show changes in decidual NK cell levels (Park et al., 2010). Whereas some other reports have shown that the assessment of peripheral blood NK cells would not

02

Conditions studied

  • Female
  • Recurrent Miscarriage
  • Unexplained Pregnancy Loss

Keywords

  • NK ;natural killer cells
03

In context

Abortion, Spontaneous

320 studies on the registry are indexed under Abortion, Spontaneous; 53 are open to participants now.

This study's planned enrollment of 60 is below the median of 200 across 140 observational studies indexed under Abortion, Spontaneous.

Browse Abortion, Spontaneous studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

We will recruit patients from outpatient clinics from Assuit University Hospital,Women fulfilling eligibility criteria will be included after careful gynecologycal examination,Those who consent to participate will be referred to the lab for investigation.

Inclusion criteria

  • 1.Age less than 40 years. 2.History of two or more spontaneous miscarriages .

Exclusion criteria

Exclusion Criteria:

    1. Age more than 35 years. 2. Women with elevated level of TSH above (2.5 mIU/ml) or prolactin above( 19.5 ng/mL)and uncontrolled DM.

      1. Women with autoimmune disorder (antiphospholipid antibody syndrome)with LA1/LA2 ratio more than( 1.2).

      4.Women receiving oral contraceptive pills.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • unexplained recurrent pregnancy loss

    peripheral blood sample examined by flowcytometry

  • control fertile multipara

    peripheral blood sample examined by flowcytometry

06

What researchers measure

Primary outcomes

  1. asses the number of Natural killer cells

    flowcytometry

    Time frame: 15 month

07

Study locations

1 site
  • Yossra Mahmoud Mohammed
    Assiut, 088, Egypt
08

References and documents

Publications

  • Fukui A, Kamoi M, Funamizu A, Fuchinoue K, Chiba H, Yokota M, Fukuhara R, Mizunuma H. NK cell abnormality and its treatment in women with reproductive failures such as recurrent pregnancy loss, implantation failures, preeclampsia, and pelvic endometriosis. Reprod Med Biol. 2015 Apr 11;14(4):151-157. doi: 10.1007/s12522-015-0207-7. eCollection 2015 Oct. PubMed 29259412 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03941470
Lead sponsor
Assiut University
Responsible party
Yossra Mahmoud Mohammed (Assesment of Natu, Assiut University) — Principal investigator
First posted
May 8, 2019
Start date
Apr 30, 2019
Primary completion
Dec 1, 2019 (estimated)
Completion
Jul 20, 2020 (estimated)
Last update
May 8, 2019

Study contacts

assiut university
principal investigator · Assiut University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion